Development of a Humanized Mouse Model for Assessing Allogeneic NK Cell Therapy Persistence and Efficacy

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Development of a Humanized Mouse Model for Assessing Allogeneic NK Cell Therapy Persistence and Efficacy

Humanized In Vivo Models for Allogeneic NK Cell Therapy Assessment

CELL & GENE | RNA | BIOLOGICS

    What is a humanized in vivo model for NK cell therapy?

    A: It is an immunodeficient research model engrafted with human immune system components, typically CD34+ hematopoietic stem cells, to create a host environment that supports the survival, expansion, and function of human allogeneic NK cells.

    Why is this model necessary for allogeneic NK cells?

    A: Standard immunodeficient models cannot predict human-specific immune interactions. A humanized system is required to accurately assess key attributes like cell persistence, potential rejection by a human immune system, and efficacy against human tumors in vivo.

    What are the key endpoints measured in these studies?

    A: Primary endpoints include tumor growth inhibition (TGI) and overall survival. Secondary and exploratory endpoints consist of NK cell persistence and trafficking measured by flow cytometry or Histology, biodistribution to key organs, and monitoring for any signs of graft-versus-host disease (GvHD).

    How does this model de-risk a clinical program?

    A: It generates predictive data on the therapeutic candidate’s in vivo behavior. This intelligence informs dose selection, clarifies the mechanism of action, and provides a robust, decision-driving dataset to support a successful Investigational New Drug (IND) application.

Humanized in vivo models provide indispensable data on the persistence, trafficking, and anti-tumor activity of allogeneic NK cell therapies. This in vivo approach is designed to mitigate clinical risk by enabling the evaluation of human-specific immune interactions within a preclinical setting. At Franklin Biolabs, we engineer these complex studies to generate the precise pharmacology and safety data required to support confident go/no-go decisions and successful regulatory submissions.

The Challenge: Predicting Allogeneic Cell Behavior In Vivo

Assessing the true potential of an allogeneic NK cell therapy presents a distinct set of challenges. Standard immunodeficient xenograft models, while useful for evaluating direct cytotoxicity, lack the human immune components necessary to model clinically relevant phenomena such as cell rejection or long-term persistence.

A successful preclinical program must generate data within a biological system that can:

  • Support the engraftment and function of therapeutic human NK cells.

  • Recapitulate the interactions between the NK cell product and a human immune system.

  • Sustain the growth of a relevant human tumor xenograft to measure anti-tumor activity.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

A Validated Approach: Translational Confidence Through Humanized Models

Humanized models provide the necessary biological context to address these challenges directly. The principle of using such advanced in vivo systems to generate high-confidence translational data has been firmly established across multiple therapeutic modalities.

For instance, early work in gene therapy demonstrated how humanized systems were instrumental in validating AAV vector efficacy and safety, showing significant therapeutic outcomes that supported clinical translation (PMID: 20976059, PMID: 22985273). This precedent of de-risking novel platforms in more clinically relevant systems underscores the value of applying the same rigorous approach to cell therapies. Our >100,000 sq ft GxP-compliant facility is fully equipped to execute these complex, long-term in vivo studies.

Core Study Design and Key Endpoints

A typical study workflow is designed to assess efficacy and persistence concurrently. The design incorporates multiple stages to generate a comprehensive dataset for IND-enabling packages.

  • Model Generation: Immunodeficient hosts are engrafted with human CD34+ hematopoietic stem cells to reconstitute a human immune system.

  • Tumor Implantation: Once human immune engraftment is confirmed, human tumor cells are implanted subcutaneously or orthotopically.

  • Therapy Administration: The allogeneic NK cell product is administered according to the planned clinical route and dosing schedule.

  • In-Life Monitoring: Key in-life measurements include tumor volume, body weight, and peripheral blood analysis via flow cytometry to track NK cell persistence.

  • Terminal Analysis: At study conclusion, tissues are collected for detailed analysis, including Histology to confirm tumor infiltration and non-target tissue biodistribution.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

IND-Enabling Data Packages

The data generated from these humanized model studies form a core component of the pharmacology section of an IND filing. By demonstrating in vivo proof-of-concept and characterizing the persistence of the cell product, these studies provide regulators with the confidence needed to approve clinical investigation. We design our studies to generate robust data packages that support navigation of the typical 18-24 month IND timeline.

Commitment to Animal Welfare

All in vivo studies are conducted under the highest ethical standards of animal care. We work within AAALAC-accredited facilities and in full compliance with applicable national regulations, adhering strictly to the 3Rs principles of Replacement, Reduction, and Refinement.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities